Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Bone Biologics (BBLG) Income from Continuing Operations (2016 - 2017)

Bone Biologics (BBLG) has disclosed Income from Continuing Operations for 2 consecutive years, with 2769609.0 as the latest value for Q4 2017.

  • On a quarterly basis, Income from Continuing Operations rose 41.05% to 2769609.0 in Q4 2017 year-over-year; TTM through Dec 2017 was 7051572.0, a 72.91% increase, with the full-year FY2025 number at 3112958.0, up 25.23% from a year prior.
  • Income from Continuing Operations was 2769609.0 for Q4 2017 at Bone Biologics, down from 2375739.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 1016302.0 in Q2 2017 to a low of 12263789.0 in Q1 2016.